MDX-1097

From WikiMD.org
Jump to navigation Jump to search

MDX-1097

MDX-1097 (pronunciation: /ɛm diː ɛks 1097/) is a monoclonal antibody designed for the treatment of multiple myeloma. It is developed by Medarex, a biopharmaceutical company specializing in the discovery, development, and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases.

Etymology

The term MDX-1097 is a proprietary name given by the company Medarex. The prefix 'MDX' stands for Medarex, and '1097' is a unique identifier for this specific antibody.

Mechanism of Action

MDX-1097 targets a specific protein found on the surface of multiple myeloma cells, known as BCMA (B-cell maturation antigen). By binding to this protein, MDX-1097 can help the immune system recognize and destroy the cancer cells.

Related Terms

  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
  • Multiple Myeloma: A type of blood cancer that begins in the plasma cells, a type of white blood cell.
  • Medarex: A biopharmaceutical company that develops antibody-based therapeutics.
  • BCMA (B-cell maturation antigen): A protein that is found on the surface of certain types of cancer cells, including multiple myeloma cells.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski